Essential Information on Trump’s New Executive Order Regarding Psychedelic Drugs

(SeaPRwire) –   President Donald Trump signed an executive order on April 18 aimed at speeding up the development of psychedelic drugs for medical use. The directive instructs the Food and Drug Administration (FDA) to fast-track the review of psychedelics meeting specific standards. It also directs the Department of Health and Human Services to allocate $50 million to match state government investments in researching psychedelics for mental-health disorders. 

Substances like LSD, MDMA (often called “Molly”), and psilocybin remain illegal under federal law. Yet, studies indicate some of these compounds could help ease conditions such as treatment-resistant depression and PTSD. Experts note that while the order does not alter the core safety and efficacy data required by the FDA, it serves as a symbolic gesture, indicating the administration’s rare willingness to view controlled substances as possible therapies. 

“Having psychedelics discussed in the Oval Office, receiving this level of prioritized focus from a president, is quite unprecedented,” stated Mason Marks, a senior fellow with the Project on Psychedelics Law and Regulation at Harvard Law School’s Petrie-Flom Center. These substances were famously in the public eye over fifty years ago when President Richard Nixon outlawed them during his “war on drugs.” Trump’s remarks, however, conveyed a markedly different sentiment. “Can I have some, please?” he quipped at the event. 

What does this mean for psychedelics as treatments?

Conducting research into the medical applications of psychedelics has historically been difficult, as has establishing a practical, evidence-based therapy using them. The FDA turned down an application to approve MDMA for PTSD two years ago, requesting more data. STAT also reported that late last year, the agency declined to grant accelerated review to Compass Pathways’ synthetic psilocybin treatment for severe depression.

Nevertheless, this new executive order is encouraging for the emerging field. “We are very pleased to see that the grounding for the executive order was the need to get new treatment options to patients who are urgently in need of them,” Kabir Nath, CEO of Compass Pathways, told TIME.

“It truly reflects changing perceptions around psychedelics, which could have a far greater future impact,” Marks said. He highlighted the $50 million in matching funds as a notable step. For state legislators hesitant about backing psychedelic research bills, “they might view this as an indication of supportive federal conditions, making them more comfortable with moving ahead.” 

Conversely, could pressure from the White House lead to the rushed approval of unsuitable treatments? “That is a concern. That wouldn’t be good for anyone,” Marks remarked. “It could significantly undo the progress achieved so far.”

What is ibogaine, and why did Trump mention it?

President Trump attributed the order to discussions with podcast host Joe Rogan, who attended the signing ceremony, concerning ibogaine. This psychedelic, extracted from the root of an African shrub, has been investigated for its possible role in treating PTSD and traumatic brain injuries, along with other applications. 

However, ibogaine can trigger deadly heart rhythm disturbances, leading to a halt in U.S. research during the 1990s. Studies in other parts of the world, such as in Mexico where ibogaine clinics exist, have been limited in scale.   

Ibogaine’s rapid emergence into the national conversation is credited to a passionate activist community. “Proponents of ibogaine therapy have effectively channeled widespread concern for veterans, and there is a genuine need,” Marks explained. “We can hope something very positive, helpful, and practical emerges from this.” 

What will this executive order change?

The White House has tasked the FDA with identifying which psychedelics could qualify for vouchers that expedite their review for approval. This would allow manufacturers of these compounds to choose to have their evidence packages assessed by regulators in 1 to 2 months, a much shorter timeframe than the typical 6 to 12 months in the standard FDA process.